Respuesta de Kusters et al a la carta relativa al artículo "Efecto de la rosuvastatina en el espesor de las carótidas íntima-media en niños con hipercolesterolemia familiar heterocigótica: el estudio CHARON (hipercolesterolemia en niños y adolescentes que toman rosuvastatina abierta) "

¹Departments of Vascular Medicine (D.M.K., M.J.A.M.B., J.J.P.K.).
²Pediatrics (D.M.K., M.J.A.M.B., A.W.).
³Lipid Clinic, Medical Department, Oslo University Hospital, Norway (G.C.).
⁴Department of Pediatrics, University of Toronto, Labatt Family Health Center, The Hospital for Sick Children, Canada (B.W.C.).
⁵Department of Hepatology and Metabolic Center, University Hospitals Leuven, Belgium (D.C.).
⁶Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, Canada (G.A.F.).
⁷Department of Medicine, University of British Columbia, Vancouver, Canada (G.A.F.).
⁸Clinique des Maladies Lipidiques de Québec Inc, Canada (C.G.).
⁹Department of Medicine, Université de Montréal, Canada (D.G.).
¹⁰Department of Pediatrics, McMaster University, Hamilton, Canada (K.M.M.).
¹¹Metabolic & Atherosclerosis Research Center, Cincinnati, OH (T.T., E.A.S.).
¹²AstraZeneca Pharmaceuticals LP, Wilmington, DE (E.M., J.R.).
¹³AstraZeneca, Macclesfield, UK (P.D.M.).
¹⁴Clinical Epidemiology, Biostatistics and Bioinformatics (B.A.H.), Academic Medical Center, Amsterdam, the Netherlands.

Resumen